Affiliation:
1. Municipal Clinical hospital № 38
2. Municipal Clinical hospital № 5
Abstract
Cholesterol atheroembolism syndrome is a systemic pathological process caused by the embolization of small arteries with cholesterol crystals, which can develop spontaneously, and it is the result of intravascular surgery and / or the use of anticoagulants. Embolization cholesterol crystals leads to ischemic and inflammatory organ damage. The clinical picture is variable, various organs can be targets, but skin and kidneys are mainly affected. Specific clinical and laboratory signs aren’t. Tissue biopsy is the gold standard for diagnosis cholesterol atheroembolism syndrome. The treatment is based on the correction of classical cardiovascular risk factors, the use of statins. In terms of benefit and risk failure from anticoagulants and thrombolytics should be considered. Studies on the use of corticosteroids, cytostatic, and colchicine have conflicting results. The use of monoclonal antibodies of IL-1 antagonists is a perspective direction.
Reference49 articles.
1. Smirnov A.V., Dobronravov V.A., Rumjancev A.Sh. et al. Acute kidney injury. M., OOO «Izdatel’stvo «Medicinskoe informacionnoe agentstvo». 2015; 488 s. ISBN 978-5-9986-0228-3 [In Russian].
2. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019; 15: 209-20. doi: 10.2147.
3. Denis Le Seve J., Gourraud Vercel C., Connault J. et al. Update on cholesterol crystal embolism. Rev Med Interne. 2020;41(4):250-7. doi: 10.1016/j.revmed.
4. Hickey T.B., Honig A., Ostry A.J. et al. Iatrogenic embolization following cardiac intervention: postmortem analysis of 110 cases. Cardiovasc. Pathol. 2019; 40: 12-8. doi: 10.1016/j. carpath.2019.01.003.
5. Agrawal A., Ziccardi M.R., Witzke C. et al. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31(3): 407-15. doi: 10.1111/joic.12483.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献